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Imaging MS now enables the parallel analysis of hundreds of biomolecules, spanning multiple
molecular classes, which allows tissues to be described by their molecular content and
distribution. When combined with advanced data analysis routines, tissues can be analyzed
and classified based solely on their molecular content. Such molecular histology techniques
have been used to distinguish regions with differential molecular signatures that could not be
distinguished using established histologic tools. However, its potential to provide an inde-
pendent, complementary analysis of clinical tissues has been limited by the very large file sizes
and large number of discrete variables associated with imaging MS experiments. Here we
demonstrate data reduction tools, based on automated feature identification and extraction, for
peptide, protein, and lipid imaging MS, using multiple imaging MS technologies, that reduce
data loads and the number of variables by 100, and that highlight highly-localized features
that can be missed using standard data analysis strategies. It is then demonstrated how these
capabilities enable multivariate analysis on large imaging MS datasets spanning multiple
tissues. (J Am Soc Mass Spectrom 2010, 21, 1969–1978) © 2010 American Society for Mass
SpectrometryMatrix assisted laser desorption/ionization massspectrometry (MALDI MS) [1] can generate bio-molecular profiles that describe the levels of
hundreds of distinct biomolecules directly from tissue [2].
Spatially-correlated analysis, MALDI imaging MS, can
simultaneously reveal how each of these biomolecules
varies in heterogeneous tissue samples [3, 4].
There is growing evidence that imagingMS is having
an impact in disease detection, particularly cancer [5].
The differential profiles found in tumors have been
used to identify specific peptides and proteins that
could act as biomarkers. Following the histologic anno-
tation of a tissue section by a pathologist, the profiles
obtained from histologically distinct regions are com-
pared. The comparison of large numbers of tissues
enables the specificity of these biomarkers to be ascer-
tained. Such histology-defined analyses have been used
to identify candidate biomarkers from prostate cancer
[6, 7], lung cancer [8], and ovarian cancer [9].
One of the potential advantages of MALDI imaging
MS is that it can define the regions of a tissue based on
their biomolecular signatures and thereby identify
those regions displaying signatures associated with a
tumor but which have not yet undergone morphologi-
cal transformation or regions that are not morphologi-
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MALDI imaging MS has found colorectal carcinoma
related proteins in histologically benign polyps [10],
revealed proteins specific to tumor interface zones
and how normal tissue adjacent to the tumor ex-
presses many of the molecular characteristics of the
tumor [11]. This untargeted molecular analysis has
even provided evidence for intra-tumor molecular
heterogeneity [12].
The ability to detect changes in disease-associated
protein expression independent of histologic annotation
has several potential clinical applications:
1. Identification of sub-regions within tumors (intra-
tumor heterogeneity within well defined histologi-
cal subgroups).
2. Identification of regions indicating biomolecular
change before morphological transformation.
3. Differentiation of tumors with overlapping histolo-
gies (within well defined histological subgroups).
Key to the development of such histology-independent
analyses are tools for efficiently analyzing the very
large datasets generated by imaging MS. An imaging
MS analysis creates a mass spectrum for every pixel of
the image, each of which contains a multitude of peaks
that describe the mass and intensity of specific biomol-
ecules. A variety of data analysis tools have been used
to investigate these rich spatio-chemical datasets [12–
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have involved a very small numbers of tissues owing to
the very large data loads produced by MALDI imaging
MS experiments.
The number of discrete channels in a MALDI imag-
ing MS experiment can also hinder the application of
many data analysis tools. For example the number of
floating point operations of a widely used singular
value decomposition algorithm, as used in principal
component an analysis, is given by
flops 14 · k ·N2 8 ·N3 (1)
where k is the number of pixels and N the number of
variables, or discrete mass channels, in a mass spectrum
[19]. The number of channels, 60 k in a TOF instrument
measured with full resolution or 500 k for an FTICR,
needs to be reduced to efficiently analyze the intrinsic
spatial variation in the tissue’s biomolecular content.
Table 1 reports the data load and number of discrete
mass channels that can be expected from an imaging
MS analysis of a small clinical tissue array containing
twenty large tissue samples (2 cm2) and imaged with a
spatial resolution of 100 m. The experiment would
yield 400 k individual mass spectra. Depending on how
the mass spectrometry is performed the total data load
can be 100–400 Gb, and the number of channels per
mass spectrum 50 k–500 k, much too large for simulta-
neous analysis of the entire dataset (a 32 bit computer
has a maximum memory allocation of 4 Gb). However,
Table 1. Typical dataloads for clinical tissue analyses using MA
following feature extraction. Original dataloads were obtained fro
imaging (MALDI-reflectron TOF), protein imaging (MALDI-linea
Data load in imagi
Number of tissues 2
Size of tissue
Spatial resolution 10
Number of pixels per tissue  2000
Total number of pixels  40000
Number of mass spectra  40000
Pep
Mass range 1000
Digitization rate
Number of channels per spectrum 6
Data load per mass spectrum 25
Total data load per tissue
Total data load for 20 tissues 10
Number of biomolecules detected  10
Total number of values  4.00
Data load per value (64 bit)
Total data load (64 bit) 30
Total data load (32 bit) 15
Data reduction factor (64 bit) 32
Data reduction factor (32 bit) 65
*The digitization rate of the FTICR is determined by the lower mass of t
In this case m/z 400 corresponds to a cyclotron frequency of approxi
criterion [32]). These settings, using a 1 M datapoint FID ensured the full lipi
a 9.4T FTICR.if the datasets were reduced to the mass spectral fea-
tures detected in each experiment the reduced data load
would allow molecular histology of small tissue arrays
(Table 1).
Several methods for reducing this data load have been
investigated. Broersen et al. [20] analyzed multiple tissues
by selecting a reduced mass range and reducing the mass
resolution by a factor of 1000 [20]. However this strategy
necessarily compromises mass resolution to a degree
that might be deemed unacceptable, and could lead
to the merging of mass spectral peaks. The smoothing
and data-reduction capabilities of discrete wavelet
transformation have been used in MALDI mass spec-
trometry for improved quantitation [21]. van de Plas et
al. have reported a preliminary investigation of the use
of wavelet transforms for MALDI imaging MS [22]. A
1D wavelet transform of each pixel’s mass spectrum
yielded an 8 reduction in data load, and number of
channels, but retained almost all spatio-chemical infor-
mation. Note: This degree of reduction is probably an
underestimate, reflecting the very low mass resolution
of the original dataset, just 6490 samples spanning the
m/z range 2800–25,000. Three-dimensional wavelet
based data reduction exceeding 100 has been reported
for hyperspectral imaging from focal plane array detec-
tors [23]. When using wavelet-based data reduction
techniques, any subsequent analysis is performed on
the wavelet coefficients and not the measured masses.
An inverse discrete wavelet transform (IDWT) can be
used to reconstruct the m/z signals [24] or the regions
imaging mass spectrometry prior to feature extraction and
periments using typical experimental parameters for peptide
F) and lipid imaging (MALDI-FTICR)
ass spectrometry
2
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data can be used to extract region-of-interest spectra
from the original MS dataset. For pathology applica-
tions, mass spectral accuracy and specificity are crucial
to be able to identify the molecules highlighted by an
analysis and to subsequently validate any results using
independent tests, e.g., immunohistochemistry for a
specific protein [6].
We have previously distilled protein imaging MS
datasets to the mass spectral features-of-interest by
extracting a manually defined peak list [17] from each
pixel’s mass spectrum. However, such manual annota-
tion is incompatible with the high throughput imaging
capabilities [25] necessary for analyzing clinical cohorts
and lacks objectivity. Here we report the development
of entirely automated feature detection and extraction
algorithms for imaging MS datasets that encompasses
improved feature detection, applicability to multiple
MS platforms, and can be used for the automated
reduction of the datasets from entire sample cohorts.
Experimental
Tumor tissue samples obtained from surgical resection
or post-mortem specimens were snap frozen in liquid
isopentane and then stored at 80 °C until sectioning. 5
m thick tissue sections were cut at 20 °C using a
cryomicrotome and stained with hematoxylin and eosin
(H an E) to check diagnosis and viability of the tissue.
For the MALDI imaging mass spectrometry experi-
ments, 12 m thick tissue sections were cut at 20 °C
and thaw mounted onto conductive glass slides (Delta
Technologies, Stillwater, MN, USA). The tissues were
then slowly brought to room temperature in a dessic-
cator and prepared for MALDI analysis of the tissue’s
peptides, proteins or lipids. All tissue samples were
handled in a coded fashion, according to Dutch national
ethical guidelines (code for proper secondary use of
human tissue, Dutch Federation of Medical Scientific
Societies).
Peptide Imaging
A uniform coating of -cyano-4-hydroxycinnamic acid
(HCCA) was added using an ImagePrep device (Bruker
Daltonics, Bremen, Germany) and a solution of 10
mg/mg HCCA in 70:30 AcN: 0.1% TFA(aq.). MALDI
imaging MS was then performed using an Ultraflex III
MALDI-TOF/TOF (Bruker Daltonics), 100 m pixel
size, and 800 laser shots per pixel (50 laser shots per
position of a random walk within each pixel). Data
acquisition, preprocessing (smoothing and baseline
subtraction of each pixel’s MALDI mass spectrum), and
data visualization/process verification were per-
formed using the Flex software suite (FlexControl 3.0,
FlexAnalysis 3.0, FlexImaging 2.1).Protein Imaging
The tissues were washed in isopropanol and sinapinic
acid (SA) matrix was added using an ImagePrep device
and a solution of 20 mg/mL SA in 70% isopropanol:
0.1% TFA(aq.). MALDI Imaging MS experiments were
then performed using an Autoflex III MALDI-TOF
(Bruker Daltonics), 100 m pixel size, and 600 laser
shots per pixel (50 laser shots per position of a random
walk within each pixel). Data acquisition, preprocessing
(baseline subtraction of each pixel’s MALDI mass spec-
trum), and data visualization/process verification were
performed using the Flex software suite (FlexControl
3.0, FlexAnalysis 3.0, FlexImaging 2.1).
Lipid Imaging
A uniform coating of 2,5-dihydroxyacetophenone ma-
trix was added using a 20 m stainless steel sieve [26]
and the tissue analyzed using either an UltrafleXtreme
MALDI-TOF/TOF or a 9.4T APEX-Ultra MALDI FTICR
(both Bruker Daltonics). Experiments performed with
the UltrafleXtreme mass spectrometer used a 100 m
pixel size with 500 laser shots per pixel (100 laser shots
per position of a random walk within each pixel) and
were acquired using the Flex software suite (FlexControl
3.3, FlexImaging 2.1, FlexAnalysis 3.3). Experiments
performed on the APEX-Ultra FTICR mass spectrome-
ter used a 200 m pixel size with 450 laser shots per
pixel (50 laser shots per position of a random walk
within each pixel) and were acquired in fully auto-
mated mode using FlexImaging 2.1, Hystar 3.4,
ApexControl 3.0. Lipid peak assignments were made by
comparing each peak’s accurate mass measurement
with the LIPID MAPS database (http://lipidmaps.org,
mass accuracy 0.005 Da).
Data reduction and data analysis was performed using
custom scripts written in Matlab (ver. 7.4.0. Mathworks).
A full description of the automated feature identification
and extraction algorithm is included as Supplementary
Information, which can be found in the electronic version
of this article. In brief, the algorithm first calculates several
different mass spectral representations of the dataset, the
mean mass spectrum, the basepeak mass spectrum and
their TIC normalized analogues. The formulae used for
the mean and basepeak representations are
mean basepeak
Im

l
j
Im,j
j
Im,max

max
l
j
(Im,j)
(2)
where Im is the intensity of the m
th channel in the mass
spectrum and j is the pixel number. It will be shown
that the use of multiple mass spectral representations
enables established peak picking methods to be used to
identify spatio-chemical features more effectively than
current methods.
Automated feature detection is then performed on
each mass spectral representation using an adapted
1972 McDONNELL ET AL. J Am Soc Mass Spectrom 2010, 21, 1969–1978form of the LIMPIC program [27]. This feature detection
method has been developed for the reliable detection
and quantitation of protein peaks in MALDI-TOF pro-
files but is also adept at identifying the sharper peaks
produced by the higher resolution reflectron-TOF and
FTICR mass spectrometers. The algorithm uses a set of
statistical tests to decompose the mass spectrum into
signal, baseline and noise.
Firstly the spectrum is divided into a series of m/z
blocks and the kurtosis of each block is calculated to
identify blocks that do not contain significant peaks
(kurtosis1). For the TOF spectra the average values of
the blocks free of significant peaks were used to inter-
polate the baseline drift, which was then subtracted
from the spectrum. The high dynamic range and high
mass resolution of the FTICR measurements, experi-
mental mass resolution of 	120k at m/z 760, led to
spectra characterized by a very low baseline. It was
found that the slow baseline drift of the FTICR spectra
was most easily estimated by interpolating between the
minima of all blocks. An m/z-dependent estimate of the
noise in each mass spectral representation was then
performed by calculating the standard deviations of the
signals in the blocks free of significant peaks and
interpolating through the entire mass range. The peak
picking algorithm then searches for localized maxima
within the mass spectra defined by the minimum peak
width. Only those peaks exceeding a user-defined
signal-to-noise threshold and a percentage basepeak
threshold (percentage of most intense peak in spec-
trum) are retained. The use of the four mass spectral
representations enabled conservative estimates of the
S/N thresholds to be used to distinguish the peaks that
provided high quality images from noisy images (Sup-
plemental Figure 5 and Supplemental Figure 6).
The peak lists from each mass spectral representation
are combined into a final, collated peak list, which is
then used to extract cross sections of the imaging MS
dataset at these peak values. These feature detection
and extraction algorithms have been incorporated into a
single workflow that can be applied to multiple MS
methods (linear TOF, reflectron TOF, and FTICR), and
which enables multiple experiments to be selected for
data reduction without additional user intervention.
The results reported in this manuscript describe the
further development of our previous data extraction
method based on the manual definition of protein peaks-
of-interest [17]. The new algorithm includes automated
and improved feature detection, automated feature ex-
traction, for multiple MS methodologies, and molecular
classes, which can be applied for the automated reduction
of imaging MS datasets from entire sample cohorts.
Results and Discussion
Example Datasets
Figure 1 shows an example MALDI imaging MS dataset
and illustrates the peptide spectra and images that canbe obtained from a human pancreas tissue section.
MALDI imaging MS datasets are normally analyzed by
using the mean mass spectrum as the mass-spectral
user-interface of the dataset. Each of the peptide peaks
can be selected to display that peptide’s image. The
images obtained from the human pancreas tissue in-
clude distributions covering most of the tissue, as well
as highly localized features corresponding to the endo-
crine peptides produced by the pancreas’ islets of
Langerhans, for example amylin (the tissue used in this
experiment was from an elderly patient with type II
diabetes).
Closer inspection of the pancreas MALDI imaging
MS dataset revealed that the mean spectrum, shown in
black, could under-represent highly localized peptides.
Figure 1 also shows the mass spectrum obtained from a
specific islet of Langerhans. This spectrum contains
high intensity peaks that were not apparent in the mean
spectrum of the tissue, and whose images displayed a
high degree of localization.
Most data analyses, and especially automated anal-
yses, are based on the calculation of the tissue’s mean
spectrum. The residual background from the surround-
ing tissue can overwhelm signals from highly localized
peptides and proteins, even after background subtrac-
tion of each pixel’s mass spectrum (as was performed
here, see Supplementary Information for details). Thus,
one of the potential advantages of MALDI imaging MS,
namely its ability to analyze heterogeneous tissues may
be undermined by the omission of localized features in
the tissue.
Biomarker discovery experiments based on a com-
parative analysis of histologically defined regions can
detect localized differences if the histologic annotation
is highly detailed. However, the annotation typically
spans larger regions containing multiple cell types.
Furthermore, as biomarker discovery experiments at-
tempt to identify candidate biomarkers with high sen-
sitivity and specificity, the analysis purposely avoids
the intra-heterogeneity and inter-heterogeneity of the
tissues. Such histology-directed analyses are unable to
distinguish between tissues that are not set apart before
the analysis, for example tumors having overlapping
histologies; nor can they detect the molecular changes
that occur before histologic transformation or occur in
areas bordering tumor masses [10, 28].
As explained in the introduction imaging MS has
been used to identify regions with differential molecu-
lar signatures that could not be distinguished using
established histologic tools. The potential of so-called
molecular histology to provide an independent, com-
plementary analysis of clinical tissues lies in its ability
to image the distributions of hundreds of biomolecules
from the same tissue section, without a priori knowl-
edge of the tissue and spanning multiple molecular
classes. The large datasets generated by imaging MS
have limited molecular histology experiments to stud-
ies encompassing a very small number of tissues. This is
especially true for lipid and metabolite imaging MS,
re no
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tion/ion-mobility-mass spectrometry imaging because
of the need to distinguish between ions of identical
nominal mass. Figure 2 shows examples of MALDI
Figure 1. Close examination of a MALDI-TOF
tissue reveals highly localized peptides, which a
Figure 2. MALDI FTICR imaging MS analyses
tissues requires ultra high mass resolution to re
have entirely different spatial distributions. Such
file sizes: human muscle sample 32.3 Gb, human braimaging MS of lipids in human muscle and human
brain tissues using ultra high mass resolution Fourier
transform ion cyclotron resonance mass spectrometry
(FTICR MS). The high mass resolution is necessary to
ing MS analysis of peptides in human pancreas
t visible in the dataset’s mean mass spectrum.
pids in human muscle (a) and human brain (b)
the high number of isobaric peaks, which can
mass resolution experiments leads to very largeimagof li
solve
highin sample 62.6 Gb.
1974 McDONNELL ET AL. J Am Soc Mass Spectrom 2010, 21, 1969–1978distinguish between the different lipid ions, which
despite having very similar masses can have very
different spatial distributions and be highly localized.
The price of high mass resolution is large file sizes
(Table 1).
Efficient and Effective Data Reduction
Data reduction routines have been developed that im-
port all of the required instrumental parameters and
then read each pixel’s mass spectrum from the propri-
etary data format. The raw or processed data can be
imported from the MALDI-TOF instruments and the
transients are imported from the FTICR, which are then
zero-filled, apodized, Fourier transformed, and con-
verted to the m/z domain. A set of mass spectral
representations are then calculated to distinguish all
features in the imaging MS dataset; this includes the
dataset’s mean spectrum, basepeak spectrum and their
TIC normalized analogues. The basepeak spectrum
displays the maximum intensity detected in the entire
imaging dataset for every m/z, consequently higher
intensity peaks are explicitly included irrespective of
how localized they are in the tissue. Note: the basepeak
representation will include the maximum ‘background
Figure 3. Automated feature detection of the p
shown in Figure 1. Four spectral representations
detected: the mean spectrum displays the mean
basepeak spectrum displays the maximum inten
TIC-normalized analogues ensure peaks under-
are also identified. The peaks from all four mass
list, which is then used to reduce the imaging MS danoise’ value for every mass value; consequently it is
crucial that every pixel’s mass spectrum is processed
using an effective smoothing and baseline subtraction
routine before data reduction [17, 29]. A detailed de-
scription of the algorithm is provided as Supplementary
Information.
Each mass spectral representation is the sum of
many thousands of individual spectra. To aid feature
detection each mass spectral representation is smoothed
and baseline subtracted before the peak selection algo-
rithm is applied. The peaks detected in each spectrum are
then collated into a final peak list, which is subsequently
used to extract each peak’s intensity from every pixel and
create the reduced image cube dataset. Figure 3 shows the
four mass spectral representations. The blue line shows
the unsmoothed mass spectral representations, the red
line the smoothed and baseline subtracted mass spectral
representations, and the green diamonds indicate the
peaks contained in the final, collated peak list. Note: to
illustrate which peaks were detected in each mass spectral
representation, the green diamonds are plotted at the
intensities of the detected peaks; if the peak was not
detected, the intensity remains zero.
Using a S/N threshold of 4 and a local estimation of
the spectrum’s noise [27] the automated feature identi-
e imaging MS dataset of human pancreas tissue
e dataset are calculated to ensure all peaks are
sity of each mass across the entire dataset, the
f each mass across the entire dataset, and their
sented due to inhomogeneous matrix coverage
ral representations are collated into a final peakeptid
of th
inten
sity o
repre
specttaset into an image cube.
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in the pancreas MALDI imaging MS dataset, of which
only 95 were detected in the mean spectrum, and
reduced the data-load from 1.1 Gb for the complete
dataset to just 3.4 Mb for the reduced (extracted)
dataset. Figure 4 shows that peaks detected in the
basepeak spectrum but not the mean spectrum can
correspond to biomolecules with a highly localized
distribution. In this case nine additional highly local-
ized peptides were detected (see Supplementary Figure
9, for spectra and images of all nine peptides), and even
for the peptides that were detected in the mean spec-
trum their relative magnification in the basepeak mass
spectral representation indicated they may be localized.
An explicit quality control mechanism has been
developed to assess the performance of the data reduc-
tion algorithm. The reduced data is exported in the
proprietary peak list format to verify that the results of
the data reduction reproduce the original imaging MS
data recorded using FlexImaging (Supplementary
Figure 8).
Figure 5 shows the results of the feature selection
algorithm applied to the 32.3 Gb MALDI-FTICR imag-
ing MS dataset of a human muscle biopsy previously
shown in Figure 2, using conservative peak selection
criteria (S/N threshold of 4 and a basepeak intensity
threshold of 0.1%). The use of multiple mass spectral
representations increased the number of peaks detected
Figure 4. Peaks highlighted in the basepeak s
highly localized peptides.in the imaging MS dataset from 344 in the mean
spectrum to 851. The subsequent removal of ions with a
mass defect not consistent with lipids [30], which are
due to species such as matrix clusters, led to a peak list
containing 712 ions (Supplementary Figure 7). This
peak list was then used to distill the entire 32.3 Gb
MALDI-FTICR dataset to an image cube containing all
712 images. Using a 64-bit data format and retaining
each pixel’s TIC, the four mass spectral representations
and a range of additional metadata (that may be used in
subsequent data analyses), the reduced data load was
34.8 Mb. Figure 4 demonstrates that this data reduction
scheme also identified lipids with localized distribu-
tions that were not selected in the mean mass spectral
representation.
Further data reduction through summing the images
of a specific lipid’s isotopomers was investigated; 218
[M  1] isotopomers and 21 [M  2] isotopomers were
detected within a mass accuracy of 1 ppm. However,
close inspection of the mean mass spectral representa-
tion revealed that many of the [M  2] isotopomer
peaks were only partially resolved. Evidently the 120 k
mass resolution of the experiment was not sufficient to
resolve all lipid ions obtained from the muscle tissue.
The low statistical probability of lipid [M  2] isomers
means the potential contribution of [M  2] isotopes
will be small for all but the most intense lipids with a
mass 1000 Da but not for larger lipids, such as
um relative to the mean spectrum can indicatepectr
degr
1976 McDONNELL ET AL. J Am Soc Mass Spectrom 2010, 21, 1969–1978gangliosides. Nevertheless, the 	900 reduction in
data load and number of variables provided by the
algorithm is sufficient to enable simultaneous multivar-
iate analysis of the data from multiple tissues analyzed
using MALDI-FTICR-MS.
It may be argued that several of the localized peaks
detected in the basepeak mass spectral representation
would also have been detected in the mean mass
spectral representation if the S/N  4 and intensity
threshold (0.1% of maximum) had been set much lower.
However, such an approach would have led to the
inclusion of a very large number of low intensity peaks
that are associated with weak, highly pixilated and thus
unreliable images (Supplementary Figure 5 and Supple-
mentary Figure 6). The basepeak mass spectral repre-
sentation allows highly localized distributions, de-
scribed by high quality mass spectral peaks, to be
distinguished from the weak, sporadic signals of unre-
liable images.
These data reduction routines efficiently reduce the
large datasets generated by MALDI-TOF and MALDI-
FTICR imaging MS experiments into an image cube
Figure 5. Automated data reduction of the MA
2 identified 851 distinct peaks, 712 of which wer
relative to the mean spectrum displayed a highcontaining the images of all features detected in thedataset, and even includes the highly localized species
that are frequently missed using typical data analysis
routines. Table 2 provides a summary of the perfor-
mance of the data reduction routines for different
MALDI imaging MS applications. Even when all data
FTICR human muscle dataset shown in Figure
ds. Peaks highlighted in the basepeak spectrum
ee of localization.
Table 2. Performance of the data reduction algorithms on
MALDI-TOF and MALDI-FTICR imaging MS datasets
Pancreas peptides Muscle lipid
Original data
Number of pixels 2155 3163
Entire dataset 1.1 Gb 32.3 Gb
Mass spectrum size 52476 channels 1048576 channels
Reduced data
Number of images 147 712
Reduced dataset
(64 bit)
3.4 Mb 34.8 Mb
Reduction factor 330 928
The reduced datasets include all data that might be used during further
analysis (each pixel’s TIC for normalization, coordinates of each pixel,
each mass spectral representation of the dataset, the experiment name,LDI
e lipicollated peak list, and peak intensities for each of the four mass spectral
representations).
ions.
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(each pixel’s TIC for normalization, each pixel’s coordi-
nates, each mass spectral representation of the dataset,
the experiment name, collated peak list, and collated
peak intensities for each of the four mass spectral
representations), the data loads associated with imag-
ing MS datasets can be reduced by a factor of 300–900.
The substantial reduction in data load and the num-
ber of discrete variables enable multiple datasets to be
combined and their data simultaneously analyzed. Fig-
ure 6 shows an optical image of two mouse brain tissue
sections that had been prepared for protein imaging MS
and were subsequently analyzed using a MALDI TOF.
After data reduction, an image mask corresponding to
the distribution of a single protein (indicated in Figure
6) was applied and principal component analysis (PCA)
performed to investigate the variance within these
protein-specific regions. Figure 6 shows that the first
principal component reveals the differences between
the two tissues whereas the second and third principal
components reveal the correlations within the defined
regions.
The low mass resolution of peptide and protein
peaks produced by MALDI and analyzed with a linear
MALDI-TOF mass spectrometer can make automated
peak selection less reliable. The low S/N of the peptide
and protein peaks in each pixel’s mass spectrum (each
pixel analyzes a very small number of cells) exacerbates
this problem; consequently on-the-fly detection of the
peaks in each pixel’s mass spectrum has been limited to
Fourier transform-type instruments (the standard mode
of operation of the Orbitrap). On-the-fly peak detection
of each pixel’s mass spectrum must balance the use of
low peak detection thresholds (to select as many of the
low S/N peaks as possible) with the increased amount
of noise retained in the dataset. The use of the four mass
spectral representations reported here, and the collation
Figure 6. Principal component analysis of spe
protein, in two adjacent mouse brain tissue sectof the resulting peak lists, allows more demanding peakselection criteria to be used while also ensuring the
detection of localized features.
Conclusion
Data reduction algorithms have been developed for
lipid, peptide, and protein imaging MS that effectively
summarize each dataset by determining multiple mass
spectral representations of each dataset and extracting
the spatial variation (MS image) of each ion above a set
of user-defined peak thresholds. The algorithms have
been explicitly designed to include (and highlight)
localized features that can be easily missed when using
standard tools based on the dataset’s mean mass spec-
trum, and provide a quality-control feature for testing
the performance of the reduction using the original,
proprietary, imaging MS analysis software. These data
reduction tools begin to address the issue of the very
large dataloads and number of variables in MALDI
imaging MS. It is hoped that the research presented
here will prompt a wider effort to establish best practice
guidelines for data reduction in MALDI imaging MS,
thus enabling the clinical potential of molecular histol-
ogy to be fully investigated.
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